MRK250103P98000
- 0.02
- 0.000.00%
Merck & Co Newsroom
Major banks rating | Truist: The biopharmaceutical Industry needs more mergers and acquisitions to recover, lowering Merck's Target Price to $110.
UBS Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $120
Truist Financial Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Merck Cut to Hold From Buy by Truist Securities
Merck & Co Analyst Ratings
Truist Financial Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $110
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
BMO Capital has lowered the Target Price for Merck to 105 dollars.
BMO Capital Downgrades Merck & Co(MRK.US) to Hold Rating, Cuts Target Price to $105
Merck & Co Analyst Ratings
BMO Capital Downgrades Merck & Co to Market Perform, Lowers Price Target to $105
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
BMO Capital Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $136
Bernstein Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $110
Morgan Stanley Maintains Merck & Co(MRK.US) With Hold Rating, Maintains Target Price $123
Bernstein Keeps Their Hold Rating on Merck & Company (MRK)
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Maintains Target Price $121
BofA Securities Maintains Merck & Co(MRK.US) With Buy Rating, Cuts Target Price to $121
Merck & Co Analyst Ratings
B of A Securities Reinstates Buy on Merck & Co, Announces $121 Price Target